main results and the role of chance: In 17 countries where all clinics reported to the ART register, a total of 361 972 ART cycles were performed in a population of 285 million inhabitants, corresponding to 1269 cycles per million inhabitants. For all IVF cycles, the clinical pregnancy rates per aspiration and per transfer were stable with 29.1 and 33.2%, respectively, and for ICSI, the corresponding rates also were stable with 27.9 and 31.8%, respectively. In FER cycles, the pregnancy rate per thawing increased to 21.3% if compared with previous years. In ED cycles, the pregnancy rate per fresh transfer decreased to 45.8% (47.4% in 2010) and increased to 33.6% (33.3% in 2010) per thawed transfer. The delivery rate after IUI-H decreased to 8.3 (8.9 in 2010), and to 12.2% (13.8% in 2010) after IUI-D. In IVF and ICSI cycles, 1, 2, 3 and 4+ embryos were transferred in 27.5, 56.7, 14.5 and 1.3% of cycles, respectively. The proportions of singleton, twin and triplet deliveries after IVF and ICSI (added together) were 80.8, 18.6 and 0.6%, respectively, resulting in a total multiple delivery rate of 19.2% compared with 20.6% in 2010, 20.2% in 2009, 21.7% in 2008, 22.3% in 2007 and 20.8% in 2006. In FER cycles, the multiple delivery rate was 13.2% (12.8% twins and 0.4% triplets). Twin and triplet delivery rates associated with IUI cycles were 9.7/0.6% and 7.3/0.3%, following IUI-H and IUI-D treatment, respectively. † ESHRE pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committee of ESHRE. ‡ limitations, reasons for caution: The method of reporting varies among countries, and registers from a number of countries have been unable to provide some of the relevant data such as initiated cycles and deliveries. As long as data are incomplete and generated through different methods of collection, results should be interpreted with caution.
Introduction
This report is the 15th annual publication of the European IVFmonitoring Consortium (www.eshre.eu/eim) under the umbrella of the European Society of Human Reproduction and Embryology (ESHRE) on European data on assisted reproductive technology (ART).
The 14 previous reports, also published in Human Reproduction (Assisted reproductive technology in Europe, 1997 Europe, -1999 , 2006 , 2008a ,b, 2009 de Mouzon et al., 2010 de Mouzon et al., , 2012 Ferraretti et al., 2012 Ferraretti et al., , 2013 Kupka et al., 2014) , covered treatment cycles from 1997 to 2010. As in the last three reports, the printed version contains the four most significant tables. In addition, a total 19 supplementary tables are available online, making this 2011 report consistent with published reports from previous years. In the future, starting with the 16th report covering data from 2012, calculations will be done using a new computerized system.
Materials and Methods
Data on ART were collected from 33 European countries, covering IVF, ICSI, frozen embryo replacement (FER), egg donation (ED), in vitro maturation (IVM), pooled data on preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) as well as frozen oocyte replacements (FOR) .
In addition to ART, data on intrauterine inseminations (IUI) using husband/ partner's semen (IUI-H) and donor semen (IUI-D) were also included.
The report includes treatments started between 1 January 2011 and 31 December 2011. Data on pregnancy outcomes are derived from follow-up of the cohort treated during this time period. All countries are asked twice to deliver results.
The method of reporting data in 2011 was similar to that used in the previous years, in order to allow comparison of results. One table with an overview of all countries was added in 2010 (Supplementary Table SI) . Some titles of the tables were changed.
The data collection forms were revised and since 2009, a few additional pieces of information were collected regarding the register characteristics (validation process, public access to individual clinical data and financial support) and the number of fresh IVF cycles performed with semen donation or surgically obtained partner's semen.
In addition, ED cycles were divided into fresh and frozen replacements and data on embryo donation were also collected.
To clarify what kind of information was needed, extra footnotes were added.
The main focus of the EIM reports is to cover the huge variety of treatments in Europe with all the different regulations and laws behind them.
Therefore, a questionnaire with six modules (online available) was send out to the coordinator of each participating country in April 2013. Data were directly entered in an online ESHRE computer system by each country coordinator. Data analysis was performed in ESHRE's central office by V.G.
After the first tables had been created, each participating country had the opportunity to correct the data in March 2014.
As is evident from the tables, the only complete data reported from all countries were on the number of aspirations and the number of centres performing ART, not IUI.
Total values (in terms of numbers and percentages) presented in the tables, refer to those countries where all data have been reported, as underlined in the footnotes.
Definitions refer to the International Committee Monitoring Assisted Reproductive Technology (ICMART) and World Health Organization glossary of ART terminology (Zegers-Hochschild et al., 2009) .
Results

Participation
The present report includes data from 33 of 51 European countries (Supplementary Table SI In contrast to the 2010 report, Macedonia was not able to send data (contributing in 2009 with 3029 cycles all together). Cyprus restarted to send in data. Albania and Turkey (one of the main contributors in 2008 with 107 clinics and 43 928 cycles) reported until 2007, but for 3 years, data for these countries have been missing in the report. Croatia and Latvia reported until 2008, but for 2 years, these countries have not reported data.
Six countries did not provide any data for a minimum of two consecutive years (2010 and 2011) (Albania, Bosnia, Croatia, Latvia, Slovakia and Turkey).
Belarus and Malta are 'new' countries. Belarus delivered data in 2011 for the first time.
The proportion of clinics reporting the data was 81.0% (82.5% in 2010) (Table I ). In 17 countries (16 in 2010 and 21 in 2009), the coverage reached 100% (Table I, Supplementary Table SIV) .
Switzerland, Montenegro and Belarus were able to report data from all but a single centre each.
In Germany, more than 95% of the centres are included. This is the result of an ongoing fundamental change in the structure of the data collection and data analysis initiated by a governmental initiative.
Participation was very low in Greece (16%), and limited in Bulgaria (23%) and Lithuania (17%). Among the countries with the largest populations, the coverage was 100% in Italy, France and UK, 97% in Germany, 82% in Russia and only 55% in Spain.
Comparing the 30 countries that provided data in 2010 and 2011 consecutively, the amount of IVF+ICSI cycles increased from 407 675 to 433 395 (6.3%).
Registers from a number of countries have been unable to provide data on initiated cycles and deliveries; in addition, several countries show a high percentage of pregnancies that are lost to follow-up.
Therefore, complete outcome data were only available on the pregnancy rate per aspiration, while some of the more reliable indicators of treatment success (clinical pregnancies and deliveries per initiated cycle) cannot be reported completely and comparing countries should be performed with caution.
Reporting methods and size of the clinics
Among the 17 countries where reporting was complete (Supplementary  Table SIV) , the register was compulsory for 15 (11 held by a National Health Authority and 4 by a Medical Organization) and voluntary for 2-both held by a Medical Organizations (Supplementary Table SIII) .
Six registers were based on individual forms, i.e. cycle-by-cycle data. Some used the core-data-description described earlier (Germond et al., 2008) . In the 16 countries with partial EIM reporting, 14 registers were voluntary, 2 compulsory. Three were held by a National Health Authority, 11 by a Medical Organization and 2 by private initiative; only 4 used individual forms.
Thirteen countries (Austria, Belarus, Belgium, Finland, France, Germany, Italy, Poland, Slovenia, Spain, Sweden, Switzerland and UK) reported some kind of data validation process.
Public access to individual clinic data was available in 11 countries: Ireland, Kazakhstan, Moldova, Montenegro, Romania, Serbia, Slovenia, Spain, Sweden, Switzerland and UK. Public (+ industry or professional society) financial support for the national registration effort was present in 20 countries, while in only 6 countries (Belarus, Denmark, Germany, Greece, Portugal and Slovenia), all the expenses were covered by the centres alone.
The distribution of clinics according to the number of cycles varied considerably among the countries (Supplementary Table SII) . For instance, small clinics, providing ,100 cycles annually, accounted for 8 out of 21 reporting centres in Romania (62%), 1 of 4 in Montenegro (33%) and 49 of 201 in Italy (27%). Austria  28  28  963  4902  811  6676  4160  812  Belarus  4  4  3  3  1272  816  107  16  5  2216  Belgium  18  34  18  28  4032  13 953  9445  605  1066  29  29 Large clinics performing .1000 cycles a year constituted 13 of 18 (72%) in Belgium, 2 of 3 in Slovenia and 6 of 13 (46%) centres in the Netherlands.
Number of treatment cycles per technique and availability
In total, 609 973 cycles were reported in 2011 (Table I )-61 945 more than in 2010 (+11.3%). Compared with 2010, two more countries reported in 2011 (Fig. 2) .
Among the 437 510 fresh cycles reported in 2011, 138 592 were IVF (32%) and 298 918 were ICSI (68%). For 10 years (between 1997 and 2007) , an increase in the proportion of ICSI to IVF cycles was described. Since 2008, a plateau seems to be established (Fig. 3) .
Among the fresh aspirations, 20 countries reported 14 117 of 262 784 cycles performed with donor semen (5.4%) and 25 countries reported 11 819 of 329 551 cycles performed with surgically obtained partner's semen (3.6%).
Information about FER-thawing was available in all countries except Belarus, Finland, Greece, Lithuania, Moldava, Serbia and the Netherlands (Table II) .
Information about FER transfer was available in all countries except Moldava and Serbia (Supplementary Table SVII) . A total of 118 072 FER-thawing cycles had been reported in 2011. A total of 118 869 FERtransfer cycles had been reported-14 808 more than in 2010.
Overall, the proportion of FER cycles compared with 'fresh' cycles was 32.3% (28% in 2010), but in some countries, the proportion was much higher: 85.8% in Switzerland; 82.2% in Finland, 55.1% in the Netherlands, 54.4% in Sweden, 54.1% in Iceland, 50.9% in Poland, 47.7% in Belgium, 41 .4% in Norway and 41.1% in the Czech Republic.
The number of ED cycles, reported by 22 countries, was 30 298 (in 2010: 22 countries with 23 625 cycles). Table I also shows the number of cycles per million women of reproductive age (15 -45 years) and per million inhabitants, in the 17 countries where data coverage was 100%. Details are reported in Supplementary  Table SIV . In Denmark, 5.8% of all infants born had been registered by an ART programme. In Italy, this number was 1.7%. Table II shows pregnancy and delivery rates per aspiration for IVF and ICSI, and pregnancy and delivery rates per thawing for FER.
Pregnancies and deliveries after treatment
Three countries (Cyprus, Hungary and Lithuania) did not provide data on deliveries. Austria provided only total cumulative deliveries after IVF and ICSI combined.
Thus, the mean pregnancy and delivery rates were computed for countries providing the relevant information.
There were significant national variations in clinical outcomes. On average, pregnancy rates per aspiration were 29.1% for IVF (29.2%in 2010) (Table II) and 27.9% for ICSI (28.8% in 2010) . In FER cycles, the pregnancy rate per thawing was 21.3% (21.5% in 2010).
For IVF, the pregnancy rate was 19.1% in Czech Republic and 50.0% in Montenegro.
As shown in Supplementary Tables SXIII and SXIV, several countries experienced difficulties in gathering full pregnancy outcome data. ART in Europe, 2011 Overall, the pregnancies lost to follow-up were 11.1% (7.3% in 2010) for IVF and ICSI and 11.4% (6.5% in 2010) for FER.
The mean delivery rates per aspiration for IVF, ICSI and FER (per thawing) were 21.7, 19.9 and 14.4%, respectively (Table II) .
These figures represent the actual recorded deliveries, even though a number of deliveries may have occurred in the lost to follow-up group.
A detailed account of numbers of cycles, aspirations, transfers, pregnancies, deliveries and the corresponding rates per technique in each country are reported in Supplementary Table SV for IVF, Supplementary  Table SVI for ICSI and Supplementary Table SVII for FER.
The number of documented miscarriages was reported by 30 countries for IVF and ICSI and by 27 countries for FER (Supplementary  Tables SXIII and SXIV) .
In these countries, the rates varied from 1.3 to 85.3% for fresh cycles (mean of 17.0%) and from 11.2 to 50.0% for FER (mean of 21.6%).
The figures may be underestimated because of pregnancies lost to follow-up.
In the nine countries with complete follow-up, the average figures were 21.0% for fresh cycles and 24.0% for FER.
ED (fresh transfer) was reported by 21 countries (Supplementary Table SVIII ). In most of the countries where data were not reported, this technique was not allowed. Since 2009, the donor cycles (aspirations) and the recipient cycles (transfers) were divided into fresh or frozen/thawed cycles.
Frozen/thawed cycles include oocyte or embryo cryopreservation. In total, 8975 clinical pregnancies resulted from 28 045 embryo transfers.
A significant number of ED are carried out using frozen oocytes. The mean pregnancy rate was 45.8% (50.4% in 2010) in fresh transfers and 33.6% (33.3% in 2010) in thawed transfers.
The mean delivery rate per donation was 39.1%. Fifteen countries reported data on embryo donation: 3153 transfers were performed, with 992 pregnancies (31.5%).
In total, 134 106 infants were born after IVF, ICSI, FER, ED and PGD in the 30 countries where the reporting included newborns (Table II) .
Of the 134 106 ART infants, 102 160 were born after IVF/ICSI fresh cycles (Supplementary Table SXIII ) and 21 156 were born after FER 1 (Supplementary Table SXIV) .
Age distribution
The age distribution of women treated with IVF and ICSI varied across countries (Supplementary Tables SIX and SX) . The highest percentages of women aged 40 years or more in IVF-cycles were found in Greece, Switzerland and Italy, whereas the highest percentages of women aged 34 years or less were found in Ukraine, Belarus and Montenegro.
As expected, pregnancy rates associated with IVF and ICSI decreased with advancing age. The same trend was seen for delivery rates.
For women ≥40 years undergoing ICSI, the delivery rates vary from 5.0% in Czech Republic to 14.9% in Kazakhstan (Supplementary  Table SX) .
FER cycles (Supplementary Table SXI) included a relatively higher percentage of young women (≤34 years: 50%) and, as in fresh cycles, pregnancy and delivery rates decreased with age.
In ED cycles (Supplementary Table SXII) , the age of the recipient was 40 years or more in 58.7% of cases on average, and few countries reported ,40%: Hungary (17.6%), Romania (34.8%), Slovenia (16.7%) and Sweden (11.4%).
Pregnancy and delivery rates in oocyte recipients were comparable across different age groups. Table III , major differences were seen between countries concerning the number of embryos transferred. In 2011, three countries reported an SET rate of over 50% (Belgium 50.4%, Finland 67.55% and Sweden 73.3%).
Number of embryos transferred and multiple births
The proportion of triple-embryo transfers ranged from 0 in Sweden and Iceland and 0.1% in Finland to ≥40% in Bulgaria, Greece, Lithuania, Moldova, Montenegro and Serbia.
The transfer of four or more embryos ranged from 0% in 15 countries and over 2% in 9 countries to 10.4% in Romania.
In FER cycles, the proportions of single, double, triple and ≥4 embryos transfers were 37.9, 53.1, 8.7 and 0.4%, while in ED, the figures were 19.7, 70.2, 9.5 and 0.6%, respectively.
In Additional data on pregnancy outcome, singleton and multiple deliveries are provided in Supplementary Tables SXIII and SXIV. In ED, of 7137 deliveries with known data on multiplicity, 1761 were twins (24.7%) and 44 were triplets (0.6%) (data not presented in tables).
Perinatal risks and complications
Supplementary Table SXV summarizes the risk of preterm deliveries according to the number of newborns. Data were available from 17 countries. These show that the risk of extreme preterm birth (gestational weeks 20 -27) increased from 0.9% (1.1% in 2010) for a singleton delivery to 3.7% (3.2% in 2010) for twins and 13.5% (12.8% in 2010) for triplets.
The same trend was noted for very preterm birth (28-32 weeks), from 2.3 to 10.4% and 32.4%, respectively. Term delivery (37+ weeks) rate was 88.0% for singleton, 46.1% for twins and only 8.6% for triplets.
Ovarian hyperstimulation syndrome (OHSS) was reported in 24 of the 33 countries (Supplementary Table SXVI ). In total, 1705 cases of OHSS were recorded, corresponding to a prevalence of 0.6% (0.4% in 2010 and 0.8% in 2009) of all stimulated cycles in the countries reporting the data. The table also includes data on the incidence of other adverse outcomes, such as bleeding (711 cases and 996 deliveries (23.3% per transfer), the main contributor being Spain with 2887 cycles. More complete data and detailed analysis of PGD/PGS in Europe will be published separately by ESHRE's PGD Consortium (Moutou et al., 2014) .
In vitro maturation
IVM was recorded in nine countries (Table I) . A total of 511 aspirations (493 in 2010, 1334 in 2009 and 562 in 2008) and 437 transfers were recorded, resulting in 127 pregnancies and 87 deliveries. Russia accounted for 55% of cycles and 75% of deliveries.
Frozen oocyte replacement
FOR was recorded by 10 countries (Table I) , with a total of 5237 thawings (4859 in 2010), 4368 transfers, 1415 pregnancies and 853 deliveries. The majority (93%) was performed in Italy and Spain.
Intrauterine insemination
The number of IUI laboratories present in the countries was recorded in 2009 for the first time. In 2011, 22 countries reported IUI cycles, with a total of 1107 units, 917 of which (83.0%) were reporting to the EIM (Table I) . Among the countries reporting deliveries, the mean delivery rate per cycle was 8.3% (8.8% in 2010), with 9.7% (9.6% in 2010) of deliveries being twin and 0.6% (0.5% in 2010) triplet deliveries.
For IUI-D, 41 151 cycles (33 596 in 2010) were reported by 21 countries, the main contributors being Denmark, Spain and Belgium. The delivery rate per cycle was 12.2% (14.1% in 2010), with multiple delivery rates of 7.3% (8.5% in 2010) for twins and 0.3% (0.2% in 2010) for triplets.
Data available on outcomes in women below 40 years and 40 years or more are presented in Supplementary Tables SXVII and SXVIII. The delivery rate associated with IUI-H declined with age (8.2% below 40 years versus 3.4% above) and the multiple delivery rate decreased from 9.1 to 5.5% for twins, and from 0.7 to 0.3% for triplets.
Similar findings were seen in IUI-D, where delivery rates decreased from 12.9 to 5.8%, twin deliveries from 7.1 to 2.1% and triplets from 0.2 to 0.0% (women below 40 versus women older than 40 years).
Sum of fresh and FER ('cumulative') delivery rates
Supplementary Table SXIX gives an estimate of a cumulative delivery rate per aspiration in countries performing FER and reporting deliveries.
The calculation, presented as the sum of fresh and FER deliveries as nominator with as denominator the number of aspirations obtained during the same year, is not a true cumulative delivery rate per aspiration, but it shows that the delivery rate (fresh versus cumulative) can increase in the countries reporting the relevant data.
Overall, the increase after inclusion of FER deliveries was from 19.7 to 24.0%, but in some countries, the rise of the delivery rates was even more significant (Finland +13.4%, Switzerland +10.2%).
In countries where the proportion of FER cycles was at least 30% of the total number of oocyte aspiration cycles, our definition of cumulative delivery rate added more than 3% to the delivery rate per fresh cycle. Italy: underestimation of deliveries because of high number of pregnancies lost to follow-up, IUI-D is forbidden. Romania: data from only 13 out of 21 clinics. The UK: for IUI-H, only the number of cycles and pregnancies are available.
Cross-border reproductive care
Only seven countries reported data on cross-border reproductive care (CBRC): Belarus, Iceland, Montenegro, Poland, Slovenia, Spain and Switzerland. A total of 3507 cycles were reported, 60.0% of which involved IVF/ICSI with the couple's own gametes, 17.6% were EDs and 21.8% were IUI or IVF with semen donation. Information regarding the countries of origin was very incomplete and not reliable enough to draw any conclusions. The main reason (45%) reported by patients was to seek a higher quality treatment than available in their home countries.
Discussion
The present report is the 15th consecutive, annual European report on ART data. Taken together, these reports cover nearly 6 million treatment cycles from 1997 to 2011. Since 2003 also the infants born after ART had been included-nearly 800 000. As shown in the tables, the method of reporting varies among countries and registers. A number of countries have been unable to provide some of the relevant data, such as initiated cycles and deliveries.
It can be argued that as long as data are incomplete and generated through different methods of collection, results should be interpreted with caution.
Nevertheless, the findings reported in this paper reveal important trends in practice and outcomes in Europe and give a clear picture of the differences existing among countries.
In comparison with 2010, the number of countries reporting to the ESHRE's EIM Consortium increased from 31 in 2010 to 33 in 2011. Albania, Bosnia, Croatia, Latvia, Macedonia, Malta, Slovakia and Turkey were not able to contribute data.
Most of the independent European states that have never contributed data are very small countries (Andorra, Armenia, Liechtenstein, Luxemburg, Monaco, San Marino and Vatican City). Data are also not available from Azerbaijan, Georgia and Kosovo, but overall, the EIM has been collecting data from nearly 80% of the European countries for several years.
This trend has been ongoing since 2009. The EIM consortium is working on support for those countries with no existing national registry or with difficulties in providing data.
In 2011, the coverage of all clinics in countries which provided data was 81.0%.
The number of countries with 100% coverage was 17-similar to 2010 (21 in 2009, 19 in 2008) .
The lowest reporting rates were from Greece (16%), Lithuania (17%) and Bulgaria (23%).
Overall, the number of reported cycles increased by 11.3% but also the number of countries increased (31 to 33). Comparing the 30 countries which reported also in 2010, an increase in IVF/ICSI cycles from 407 675 to 433 395 could be demonstrated (6.3%).
In Russia, 63% more cycles were registered in 2011 compared with 2010, while Greece increased by 59%. On the other hand, the treatment cycles decreased in Bulgaria (62%) and Ireland (28%).
Clear reasons for this trend are not distinct, but the economic situation could be addressed here.
In 2011, the USA (CDC, 2012) reported 101 213 started IVF/ICSI cycles (100 824 in 2010).
For Australia and New Zealand, 40 696 initiated cycles were reported (47 260 in 2010) (Macaldowie, 2015) .
The structure of data collection, legal conditions and insurance systems can influence not only the amount of treatment cycles per inhabitant but also success rates. This has to be taken into account by comparing different annual reports.
As shown in Table I and Supplementary Table SIV , the average number of treatment cycles per million inhabitants in the countries with 100% coverage was 1269 (1214 in 2010) , while the average number of treatment cycles per million females of reproductive age (15 -49 years) was 6556 (6221 in 2010).
Huge differences in access (cycles/million females of reproductive age) exist among countries, with the highest figures from Belgium (14 930), Denmark (13 824) and Iceland (11 366), and the lowest from Hungary (2289).
Countries able to provide over 10 000 cycles per million women of reproductive age and over 2000 cycles per million inhabitants were Belgium, Denmark, Iceland, Slovenia and Sweden.
Overall, the highest availability was reported by Belgium, Slovenia and the Nordic countries. Finally, the percentage of newborns conceived through ART varied from 0.2% in Romania to 5.8% in Denmark.
The pregnancy rate per aspiration remained relatively stable for IVF at 29. 1% (2010: 29.2%, 2009: 28.9%, 2008: 28.7%) . For the ICSI treatment, for the first time, a pregnancy rate of ,28% was reported: 27.9% (2010: 29.8%, 2009: 28.5%, 2008: 28.7% (2009: 19.3 and 21.5%, 2008: 20.4 and 22.7%) .
The delivery rate per thawing for FER (14.4%) was stable (2010: 14.3%, 2009: 13.3%, 2008: 13.7%) , but this indicator of outcome may be always strongly influenced by the missing data on deliveries.
After a small decrease in 2009, the proportion of ICSI versus conventional IVF procedures showed similar percentages (ICSI 68.0%) compared with data from the previous year (Fig. 3) .
The figure is likely to have been driven by the absence of data from Turkey, a country with a very high proportion of ICSI cycles (98%) in 2008. Table I demonstrates a marked variation in the relative proportions of IVF and ICSI within Europe, and the difference seems to have a geographic distribution.
In several countries from northern and eastern Europe (Belarus, Montenegro, Kazakhstan, Norway, Iceland), IVF remains the dominant technology. In contrast, in most countries from western and central Europe (Austria, Greece, Italy, Montenegro, Poland, Spain, Switzerland), ICSI was used in a minimum of 80% of cases.
In Australia and New Zealand, 67.8% of all cycles used ICSI in 2011 and in the USA, the corresponding figure was 67%, reflecting an uniform trend throughout the world in performing ICSI in the majority of the cycles.
The marked increase in the use of ICSI cannot be explained by a similar increase in male infertility but rather by a more liberal use of this technique in cases with mixed infertility, unexplained infertility, mild male factor infertility, low oocyte number and fertilization failures (Jain and Gupta, 2007; Nyboe Andersen et al., 2008b) . ART in Europe, 2011 This is, however, unlikely to fully account for the observed differences, which can only be explained by differences in professional strategy, clinical decision-making, insurance-strategies and/or financial incentives.
Overall (Table III) .
For the third time since 1997, the proportion of 3+ embryos transfers was ,20% and the proportion of SETs was higher than that of triple embryos transfers (Fig. 4) .
The highest proportions of SETs were found in Finland (72.5%), Norway (58.2%), Sweden (73.3%), Belgium (51.2%) and Denmark (42.4%).
In contrast, ≥50% of 3+ embryo transfers were reported in Lithuania, Greece, Moldova, Montenegro and Serbia.
The EIM reports are unable to discriminate between elective (intended) SET (eSET) versus SET in general (unintended), but the increase in the number of transfers of one embryo seen in recent years is undoubtedly due to an increase in eSET.
Despite huge differences in embryo transfer policy across countries, the overall trend towards transferring fewer embryos seen over the last 10 years seems to continue (Clua et al., 2012) .
In comparison with the situation in Europe, data from other registers show that SET was performed in 73.2% (2010 69.6%) of cycles in Australia and New Zealand (Macaldowie et al., 2011) and 17% in the USA (CDC, 2011).
Similar observations can be made for the multiple delivery rates. In 2011, the multiple delivery rates (twins + triplets) in IVF and ICSI cycles were marginally lower with the previous years: 2011: 18.6% and 0.6%, 2010: 19.6% and 1.0%, 2009: 19.4% and 0.8% (Table III) .
Overall, a remarkable reduction in triplet deliveries over the years is seen (3.6% in 1997 and 0.6% in 2011), but major differences are still evident across countries.
Some countries registered a high triplet delivery rate, most particularly Moldova (6.5%), Serbia (5.9%) and Greece (3.5%). Several other countries were able to maintain the triplet deliveries at ≤0.2% (Belgium, Czech Republic, Finland, France, Iceland, Ireland, Montenegro, Norway, Portugal, Slovenia, Sweden and The Netherlands).
The twin delivery rate ranged from 4.8% in Sweden to 41.6% in Greece.
We have included data describing preterm birth rates according to the number of fetuses in the pregnancy (Supplementary Table SXV) , which was completed by 17 countries. The risk of extreme preterm birth (,28 weeks) was increased 4-fold for twins and 15-fold for triplets (0.9 -13.5%).
The risk of very preterm birth (28-32 weeks) is increased almost 4-fold for twins and 14-fold for triplets (2.3-32.4%).
Fetal reductions are almost always performed in triplet or higher order gestations. Thus, when analysing the range of triplet delivery rates in different countries, the number of fetal reductions should also be considered. A total of 343 procedures were reported (98 less than in 2010) (Supplementary Table SXVI) . However, the number is likely to be an underestimate, since several countries, including large countries such as Germany and Italy, did not report on this intervention. Without fetal reductions, the proportion of triplet pregnancies and triplet deliveries would have been much higher.
The delivery rates in Europe remain lower than in the USA, where in fresh non-donor cycles performed in 2011, the delivery rate (live birth) per aspiration was 32.6% (33.7% in 2010) and the delivery rate per transfer was 35.8% (36.8% in 2010) (CDC, 2011) .
However, outcomes in Europe were very similar to those achieved in Australia and New Zealand, where the delivery rates (live deliveries) in fresh cycles were 18.6% (20.2% in 2010) per aspiration and 22.3% per transfer (23.6% in 2010) (AIHW, 2011) .
Data on deliveries and infants must be considered and compared with some caution because of the difficulties met by several European countries in collecting pregnancy outcome data (Supplementary Table SXIV) , while the pregnancy loss to follow-up was low in the annual reports both in the USA and in Australia/New Zealand.
Figures for multiple-infant birth rate (twins, triplets or more) point to important differences between the USA (28.8%), Europe (19.2%) and Australia/New Zealand (13.1%).
With the noticeable decline in the number of embryos transferred and the increasing proportion of FER cycles, the cumulative delivery rate per started cycle may be the most relevant end-point for ART.
However, this figure can only be obtained a few years after the initial oocyte aspiration.
In Supplementary Table SXIX, the cumulative delivery rate is presented as the sum of fresh and FER pregnancies obtained in the same calendar year. The method of calculation can be methodologically criticized, but the estimate may be close to the actual figure. In several countries, FER deliveries added substantially to the delivery rates per cycle:
Finland (20.4-33.8%), Belgium (18.9-26.2%), Sweden (22.2-31.3%) and Norway (20.9-26.9%), supporting their embryo transfer and freezing policies.
Regarding direct risks of ART, OHSS was recorded only in 0.6% of all stimulated cycles. However, there may be a degree of under-reporting of this complication as the rate varied between 0 and 2.6% in the countries reporting it (Supplementary Table SXVI) .
For the 10th consecutive year, the present report includes European data on treatments with IUI-H (174 390 cycles) and IUI-D (41 151), which is similar to 2010. Since the inception of IUI data collection, no significant differences have been noted in terms of delivery rates and in the incidence of multiple pregnancies, but the data do not allow a distinction in reproductive outcome between IUI after natural cycles or after hormonal stimulation.
In 2009, the EIM Consortium decided to continue to address the phenomenon of CBRC. An optional module was added to the data collection sheets asking for the numbers of CBRC patients, the type of treatment requested, main countries of origin and the reason for travelling abroad. Only a total of 3507 cycles were reported by seven countries. As in 2009 and 2010, the number was much lower compared with the estimation, based on the CBRC study performed in Europe (Shenfield et al., 2010) : 11 000-14 000 patients and 25 000 -30 000 cycles per year.
In addition, only incomplete information was reported regarding the countries of origin and reasons for travelling.
In summary, the 15th ESHRE report on ART for Europe shows a continuing moderate expansion in the number of treatment cycles, with more than 600 000 cycles reported in 2011. The use of ICSI has reached a plateau.
Pregnancy and delivery rates after IVF remained relatively stable, compared with 2009 and 2010. In ICSI cycles, pregnancy and delivery rates were slightly reduced. The number of multiple embryo transfers (3+ embryos) and the multiple delivery rate have shown again a clear decline.
